Natco Pharma shares rise 2% on Pomalidomide capsules launch in US

Natco Pharma

Natco Pharma’s share price rose more than 2 percent in the opening trade on March 4 after the company announced the launch of Pomalidomide Capsules in the US market.

At 09:24am,  Natco Pharma was quoting at Rs 981.00, up Rs 24.60, or 2.57 percent, on the BSE.

Natco Pharma, along with its partner Breckenridge Pharmaceutical, Inc., has launched Pomalidomide Capsules, a generic version of Pomalyst by Celgene, in the United States, according to the company’s exchange filing.

Pomalidomide Capsules, a thalidomide analogue, are indicated for the treatment of adult patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor, and have demonstrated disease progression on or within 60 days of completion of the last therapy.

The drug is also approved for AIDS-related Kaposi sarcoma after failure of highly active antiretroviral therapy (HAART), as well as for HIV-negative adult patients with Kaposi sarcoma. The product is available in 1 mg, 2 mg, 3 mg and 4 mg strengths and is primarily distributed through specialty pharmacies and clinics.

“We are pleased to launch Pomalidomide Capsules in the US. This further strengthens our oncology and specialty portfolio in the US. The launch highlights our commitment to making specialty medicines accessible to patients worldwide. We look forward to bringing more complex and specialty products to the market in the coming years,” said Rajeev Nannapaneni, Vice Chairman and Chief Executive Officer of Natco Pharma.

Catch all the market action on our live blog

In February, Eris Lifesciences announced a strategic partnership with Natco Pharma for the commercialisation of Semaglutide in India.

In the previous trading session, the share closed at Rs 956.40, down Rs 31.90, or 3.23 percent. The share touched a 52-week high of Rs 1,059.60 and a 52-week low of Rs 660.05 on 24 July, 2025 and 07 April, 2025, respectively. Currently, the stock is trading 9.74 percent below its 52-week high and 44.9 percent above its 52-week low. The market capitalisation of the company stands at Rs 17,130.07 crore.